Overview
- Lilly will buy all outstanding Ventyx shares for $14.00 each, valuing the company at about $1.2 billion.
- The price reflects roughly a 62% premium to Ventyx’s 30-day volume-weighted average, according to the companies.
- Ventyx adds oral NLRP3 inhibitors and other clinical programs spanning cardiometabolic, neurodegenerative and autoimmune diseases.
- October Phase II data for VTX3232 showed a 64% drop in a heart-disease biomarker over 12 weeks versus a 3% rise on placebo.
- The definitive deal follows reports of advanced talks that sent Ventyx shares up about 62% after hours, and it positions Lilly against rivals pursuing NLRP3 drugs such as Novo Nordisk and Roche.